• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Quick Take: Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer

byAliya Ramjaun
July 13, 2019
in Chronic Disease, Endocrinology, Neurology, Oncology, Psychiatry
Reading Time: 2 mins read
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Share on FacebookShare on Twitter

Androgen deprivation therapy (ADT) is used in the treatment of prostate cancer, either alone or in combination with other treatment modalities. ADT, however, is not without long-term effects, with patients commonly experiencing sexual dysfunction, in addition to conferring an increased risk of cardiovascular events. ADT exposure may also increase the risk of cognitive dysfunction. In this retrospective cohort study, 154,089 elderly men diagnosed with prostate cancer (1996-2003) were identified through the National Cancer Institute’s Surveillance, Epidemiology and End Results-Medicare linked database, and followed up to assess the association between ADT exposure and the diagnosis of Alzheimer disease or dementia in this patient population. Researchers found that ADT exposure was associated with a diagnosis of Alzheimer’s disease (difference 3.7%, 95% CI 3.3% to 3.9%, p<0.001; HR 1.20, 95% CI 1.17 to 1.24) and dementia (difference 5.8%, 95% CI 5.4% to 6.2%, p <0 .001; HR, 1.20, 95% CI 1.17 to 1.24). Based on survival analyses, there was also evidence of a dose-dependent association, where the time to outcome was relatively decreased in patients that received 1 to 4 doses of ADT (HR 1.19, 95% CI 1.15 to 1.24 for Alzheimer disease; HR 1.19, 95% CI 1.15 to 1.23 for dementia) compared to those that received 5 to 8 doses of ADT (HR 1.28, 95% CI 1.22 to 1.35 for Alzheimer disease; HR 1.24, 95% CI 1.19 to 1.29 for dementia). This study therefore shows that in elderly patients with prostate cancer, ADT exposure may be associated with an increased risk of Alzheimer’s disease or dementia in later life.

Click to read the study in JAMA Oncology

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

2 Minute Medicine Rewind October 12, 2026

Earlier menopause is associated with faster cognitive decline and greater late-life brain changes

Dementia diagnosis underreporting is common and associated with reduced care engagement

Tags: Alzheimer’s diseaseandrogen deprivation therapy (ADT)dementiaprostate cancer
Previous Post

#VisualAbstract: Association of Step Volume and Intensity With All-Cause Mortality in Older Women

Next Post

Residents of disadvantaged neighborhoods who are discharged from safety-net hospitals have high hospital readmission risk

RelatedReports

Weekly Rewinds

2 Minute Medicine Rewind October 12, 2026

October 12, 2026
Longevity

Earlier menopause is associated with faster cognitive decline and greater late-life brain changes

October 5, 2026
Quick Take: Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine
Chronic Disease

Dementia diagnosis underreporting is common and associated with reduced care engagement

August 29, 2026
Neurology

Older married couples demonstrate domain-specific cognitive concordance 

August 28, 2026
Next Post
Quick Take: Impact of scribes on emergency medicine doctors’ productivity and patient throughput: multicentre randomised trial

Residents of disadvantaged neighborhoods who are discharged from safety-net hospitals have high hospital readmission risk

Quick Take: State Gun Laws, Gun Ownership, and Mass Shootings in the US: Cross-Sectional Time Series

Stricter state gun laws associated with lower pediatric firearm injury

Differences in sudden unexpected infant death rates reported between states

Quick Take: Disclosure of infant unsafe sleep practices by African American mothers in primary care settings

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind October 12, 2026
  • Gepotidacin (Blujepa) is safe and effective in women with uncomplicated urinary tract infections
  • Most routine blood tests do not require prolonged fasting
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.